
Tango Therapeutics doses first subject in trial for MTAP-deleted tumours
Tango Therapeutics has announced the first subject dosing in the open-label, multi-centre TNG456 Phase I/II trial in those with methylthioadenosine phosphorylase (MTAP)-deleted solid tumours, mainly focusing on glioblastoma (GBM). Pharmacokinetics, …